Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.98 USD | +1.01% | -1.52% | -49.05% |
May. 21 | JPMorgan Adjusts Teladoc Price Target to $16 From $19, Maintains Neutral Rating | MT |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.05% | 1.86B | D+ | ||
+78.57% | 584M | - | - | |
+4.72% | 451M | - | ||
-72.81% | 120M | C- | ||
-31.22% | 87.79M | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TDOC Stock
- Ratings Teladoc Health, Inc.